Par receives FDA approval for generic version of Cefzil antibiotic

By Angela McDaniels

Seattle, Dec. 30 - Par Pharmaceutical Cos. Inc. said the Food and Drug Administration has approved the company's Abbreviated New Drug Application for Cefprozil for oral suspension in 125 mg/5 mL and 250 mg/5 mL strengths.

Par will begin shipping the product immediately.

Cefprozil is the generic version of Bristol-Myers Squibb Co.'s broad-spectrum cephalosporin antibiotic Cefzil. Sales of Cefzil for oral suspension exceed $100 million annually in the United States, the company said.

Spring Valley, N.Y.-based Par develops, manufactures and markets generic and branded pharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.